Sana biotechnology reports fourth quarter and full year 2024 financial results and business updates

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable c-peptide production post-transplant

SANA Ratings Summary

SANA Quant Ranking